Results 71 to 80 of about 1,042 (177)

Treatment Safety in Pediatric Atopic Dermatitis [PDF]

Purpose The purpose of this study is to compare the safety and long-term effects of topical calcineurin inhibitors (TCIs) and topical corticosteroids (TCS) in pediatric patients diagnosed with atopic dermatitis (AD), and to compare the prescribed ...
Ecalnir, Malia
core   +2 more sources

Model-based meta-analysis to optimise S. aureus-targeted therapies for atopic dermatitis [PDF]

, 2022
Several clinical trials of Staphylococcus aureus (S. aureus)-targeted therapies for atopic dermatitis (AD) have demonstrated conflicting results regarding whether they improve AD severity scores.
Irvine, A, Miyano, T, Tanaka, R
core   +1 more source

Atopic Comorbidities Associated With Chronic Spontaneous Urticaria: A Case‐Control Analysis of the All of Us Research Program

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Chronic spontaneous urticaria (CSU) is a mast cell‐driven condition defined by recurrent wheals and/or angioedema lasting over 6 weeks without an identifiable trigger. Though CSU is known to co‐occur with atopic diseases and share Th2‐dominant immunologic pathways, prior studies have not adequately addressed these relationships in ...
Julian A. Cortes, Nana Ama Adjei‐Frimpong, Savannah K. Fakhouri, Francesco Delacqua, Reid Oldenburg   +4 more
wiley   +1 more source

Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki, Ryo Saito, Kenta Suzuki, Daisuke Watanabe, Masako Minami‐Hori, Hirofumi Kamada, Hiroo Amano, Akihiko Uchiyama, Sei‐ichiro Motegi, Machiko Kamura, Kazunari Sugita, Noriko Kubota, Toshifumi Nomura, Maki Ozawa, Toshiya Takahashi, Takashi Yamakita, Kazumitsu Sugiura, Tetsuharu Ikegami, Ken Igawa, Yuka Kimura, Yoko Kataoka, Ryoichi Kamide, Masakazu Takahashi, Akio Tanaka, Mariko Sugawara‐Mikami   +24 more
wiley   +1 more source

Treatment Satisfaction, Efficacy, and Safety of Delgocitinib Ointment Following Switch From Topical Corticosteroids for Trunk and Extremity Rash in Atopic Dermatitis

The Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory disease characterized by recurrent remissions and relapses. Topical anti‐inflammatory steroids are commonly used for treatment, but their long‐term use poses concerns because of potential side effects. Delgocitinib ointment, a Janus kinase inhibitor, has demonstrated efficacy in several clinical
Masatoshi Abe, Atsuyuki Igarashi, Hiroyuki Kitajima, Hiroyuki Toyama, Kenji Kabashima, Hidehisa Saeki   +5 more
wiley   +1 more source

Divergent in situ expression of IL‐31 and IL‐31RA between bullous pemphigoid and pemphigus vulgaris [PDF]

, 2023
Bullous pemphigoid (BP) and pemphigus vulgaris (PV) are two major autoimmune blistering skin diseases. Unlike PV, BP is accompanied by intense pruritus, suggesting possible involvement of the pruritogenic cytokine IL-31.
Aksu, Ayşe Esra Koku, Aoki, Rui, Bağcı, Işın Sinem, Calabrese, Laura, Ergun, Ecem Zeliha, Flaig, Michael J., French, Lars E., Gürel, Mehmet Salih, Hartmann, Daniela, Horváth, Orsolya N., Manav, Vildan, Ruzicka, Thomas, Satoh, Takashi K., Sárdy, Miklós   +13 more
core   +1 more source

Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study

The Journal of Dermatology, EarlyView.
ABSTRACT Tralokinumab, an anti‐IL‐13 antibody, is effective for atopic dermatitis (AD); however, its long‐term (> 1 year) effectiveness specific to each anatomical site is unknown in real‐world settings. To evaluate 72‐week effectiveness of tralokinumab on different anatomical sites in AD, we studied 208 patients with moderate‐to‐severe AD treated with
Mizuki Shiba, Teppei Hagino, Akihiko Uchiyama, Hidehisa Saeki, Eita Fujimoto, Sei‐ichiro Motegi, Naoko Kanda   +6 more
wiley   +1 more source

Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis [PDF]

BACKGROUND AND AIMS: Pruritus is a debilitating symptom for many people living with primary biliary cholangitis (PBC). In studies with seladelpar, a selective PPAR-delta agonist, PBC patients experienced significant improvement in pruritus and reduction ...
Bowlus, Christopher L, Choi, Yun-Jung, Hirschfield, Gideon M, Johnson, Jeff D, Jones, David E, Kremer, Andreas E, Levy, Cynthia, Mayo, Marlyn J, McWherter, Charles A   +8 more
core   +1 more source

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

Comorbidities and Healthcare Utilization in 4197 Patients With Prurigo Nodularis in Israel: A Cross‐Sectional Population‐Based Analysis

International Journal of Dermatology, EarlyView.
ABSTRACT Background Prurigo nodularis patients face a significant burden of comorbidities, necessitating a comprehensive approach to care. We aimed to explore the association between prurigo nodularis, its comorbid conditions, and healthcare usage patterns.
Yuliya Valdman‐Grinshpoun, Andrea Zaga, Arnon Dov Cohen, Yochai Schonmann, Tali Czarnowicki   +4 more
wiley   +1 more source